new fda ruling on tirzepatide to reconsider removal of Eli Lilly weight loss drug from shortage list FDA Allows Compounded Tirzepatide During

As previously described ( lacZ reporter

Quoted verbatim: "Removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A." Accessed July 25, 2026

Precauciones en pacientes con: Historia de pancreatitis Enfermedad renal grave o insuficiencia renal Gastroparesia diabtica u otros trastornos de vaciamiento gstrico severos Retinopata diabtica (requiere monitoreo oftalmolgico) Ideacin suicida activa o antecedentes (para Zepbound) La decisin de iniciar tirzepatida debe tomarse mediante evaluacin mdica integral que incluya historia clnica completa, examen fsico y anlisis de laboratorio relevantes (A1C, funcin renal y heptica, perfil lipdico

References: Pickart L, Margolina A

We're a physician-supervised telehealth platform specializing in GLP-1 weight loss medication and peptide wellness therapy